Chronic Urticaria Or Hives - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Urticaria Or Hives - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Chronic Urticaria Or Hives - Pipeline Review, H2 2015', provides an overview of the Chronic Urticaria Or Hives's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Urticaria Or Hives and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Urticaria Or Hives pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Urticaria Or Hives Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Urticaria Or Hives - Overview 9
Chronic Urticaria Or Hives - Therapeutics under Development by Companies 10
Chronic Urticaria Or Hives - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Chronic Urticaria Or Hives - Products under Development by Companies 16
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development 17
3SBio Inc. 17
AstraZeneca Plc 18
Biofrontera AG 19
Celgene Corporation 20
ELORAC, Inc. 21
FAES Farma SA 22
Genentech, Inc. 23
GlaxoSmithKline Plc 24
Mabtech Limited 25
Merck & Co., Inc. 26
Mycenax Biotech Inc. 27
Novartis AG 28
Panacea Biotec Limited 29
Chronic Urticaria or Hives - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AZD-1981 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BF-Derm-1 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
bilastine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BP-001 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
cidoxepin hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
desloratadine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
fexofenadine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GSK-2646264 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
JDP-205 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ligelizumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
omalizumab biosimilar - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
omalizumab biosimilar - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
omalizumab biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
omalizumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
omalizumab biosimilar - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
quilizumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
romidepsin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Chronic Urticaria Or Hives - Recent Pipeline Updates 61
Chronic Urticaria or Hives - Dormant Projects 64
Chronic Urticaria Or Hives - Discontinued Products 65
Chronic Urticaria Or Hives - Product Development Milestones 66
Featured News & Press Releases 66
Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico 66
Apr 27, 2007: Schering-Plough declared EU Approval of Two New Formulations of AERIUS (Desloratadine). 66
Sep 07, 2006: Schering-Plough Launched Important Multinational Studies in order to Evaluate AERIUS (Desloratadine) Based Upon New Treatment Guidelines. 66
Aug 25, 2005: CIMA LABS' OraSolv Technology Used in CLARINEX (desloratadine) Disintegrating tablet Re-formulation. 67
Jul 15, 2005: FDA Approved Re-Formulated CLARINEX (desloratadine) Disintegrating Tablets 67
Nov 01, 2004: Clarinex syrup was approved for children. 68
May 19, 2004: Allex (Desloratadine): Withdrawal of the marketing authorization in the European Union 68
May 29, 2003: Schering-Plough declared CLARINEX Disintegrates Tablets Launched For Indoor and Outdoor Allergies and Chronic Idiopathic Urticaria. Non-sedating relief of indoor and outdoor allergies available in an orally disintegrating formulation. 68
Feb 25, 2003: Schering-Plough declared CLARINEX Granted Six Months Additional Marketing Exclusivity, Updates Status of CLARINEX Formulations. 69
Nov 22, 2002: CLARINEX (Desloratadine) was Honored With Outstanding Web Site Award by Web Marketing Association 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H2 2015 9
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Comparative Analysis by Unknown Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Chronic Urticaria Or Hives - Pipeline by 3SBio Inc., H2 2015 17
Chronic Urticaria Or Hives - Pipeline by AstraZeneca Plc, H2 2015 18
Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2015 19
Chronic Urticaria Or Hives - Pipeline by Celgene Corporation, H2 2015 20
Chronic Urticaria Or Hives - Pipeline by ELORAC, Inc., H2 2015 21
Chronic Urticaria Or Hives - Pipeline by FAES Farma SA, H2 2015 22
Chronic Urticaria Or Hives - Pipeline by Genentech, Inc., H2 2015 23
Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2015 24
Chronic Urticaria Or Hives - Pipeline by Mabtech Limited, H2 2015 25
Chronic Urticaria Or Hives - Pipeline by Merck & Co., Inc., H2 2015 26
Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc., H2 2015 27
Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2015 28
Chronic Urticaria Or Hives - Pipeline by Panacea Biotec Limited, H2 2015 29
Assessment by Monotherapy Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Chronic Urticaria Or Hives Therapeutics - Recent Pipeline Updates, H2 2015 61
Chronic Urticaria Or Hives - Dormant Projects, H2 2015 64
Chronic Urticaria Or Hives - Discontinued Products, H2 2015 65